NIKKEI 225
38,202.37 0.00 (0.00%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.29 +0.30 (+0.38%) GOLD FUTURES
2,315.80 -6.50 (-0.28%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,053.78 -911.75 (-1.82%)
Everest Medicines Ltd (6HN.MU)
| Previous close | 2.9600 |
| Open | 2.8600 |
| Bid | 2.8000 x N/A |
| Ask | 2.9200 x N/A |
| Day's range | 2.8600 - 2.8600 |
| 52-week range | 1.2800 - 3.7200 |
| Volume | |
| Avg. volume | 16 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireEverest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China has approved the New Drug Application (NDA) for VELSIPITY® (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). It marks the firs
PR NewswireEverest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced that the Hong Kong Department of Health had approved Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. Hong Kong marks the fourth region in Everest territories that Nefecon® received New Drug Application (NDA) approval after Singapore, Macau and mainland China. Nefecon® received full U.S. Food and Drug Administration (FDA) approval in December 2023.
PR NewswireEverest Medicines Announces Financial Results for Full Year Ended December 31, 2023
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for the full year ended December 31, 2023, along with a corporate update.
